Brief Summary:

This phase II trial studies how well pembrolizumab works in treating patients with stage IB-IV mycosis fungoides. Antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread.

For participation and/or eligibility criteria, visit Clinicaltrials.gov website provided below.

Website: https://clinicaltrials.gov/ct2/show/NCT03695471?term=mc1788&draw=2&rank=1

PRIMARY OBJECTIVE:

To evaluate the antitumor activity of pembrolizumab in patients with advanced mycosis fungoides (MF) as initial systemic therapy.

Sponsor:

Mayo Clinic

Collaborator:

National Cancer Institute (NCI)

Information provided by (Responsible Party):

Mayo Clinic

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. 

Please refer to this study by its ClinicalTrials.gov identifier: NCT03695471